Acceleron Pharma, Inc.
Clinical trials sponsored by Acceleron Pharma, Inc., explained in plain language.
A subsidiary of Merck, focused on developing therapies for rare and pulmonary diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for severe lung disease: drug delays death and hospitalization
Disease control CompletedThis study tested a drug called sotatercept in 173 people with severe pulmonary arterial hypertension (PAH), a serious lung condition that makes the heart work too hard. Participants received either the drug or a placebo on top of their usual treatments. The goal was to see if th…
Phase 3 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug shows promise for Hard-to-Treat lung condition in heart failure
Disease control CompletedThis Phase 2 trial tested a drug called sotatercept in 164 adults with a type of high blood pressure in the lungs caused by heart failure. The study compared sotatercept to a placebo to see if it could improve blood flow and walking distance. The goal is to find a better treatmen…
Phase 2 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC